Get the Stockscreener App
1.16
4.50%
0.05
Pre-market:
1.16
Coherus Biosciences Inc stock is traded at $1.16, with a volume of 1.83M.
It is up +4.50% in the last 24 hours and down -30.12% over the past month.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
See More
Previous Close:
$1.11
Open:
$1.15
24h Volume:
1.83M
Relative Volume:
0.37
Market Cap:
$134.43M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.4462
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
+4.50%
1M Performance:
-30.12%
6M Performance:
-14.07%
1Y Performance:
-43.69%
1-Day Range:
$1.11
$1.23
1-Week Range:
$1.095
$1.39
52-Week Range:
$0.6603
$2.87
Coherus Biosciences Inc Stock (CHRS) Company Profile
Name
Coherus Biosciences Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Biosciences Inc
|
1.16 | 134.43M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Biosciences Inc Stock (CHRS) Latest News
Coherus BioSciences's SWOT analysis: stock faces headwinds amid oncology pivot - MSN
Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat
Positive Phase II trial results for Coherus' casdozokitug - The Pharma Letter
Coherus Presents Final Phase 2 Clinical Casdozokitug - GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ... - The Bakersfield Californian
CHRS (Coherus BioSciences) Market Cap : $160.1 Mil (As of Jan. 21, 2025) - GuruFocus.com
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Coherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St
Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire
Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha
Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat
California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN
Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board - Investing.com
Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider
Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Coherus Biosciences Announces Board Member Resignation - TipRanks
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia
Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP
Accord acquires Coherus’ Udenyca business - The Pharma Letter
Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers
Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights
S&P 500 Total Return (TCM23) Quote - The Globe and Mail
Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues
Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
Redwood City-based Coherus' stock surges after major drug sale - The Business Journals
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive
Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma
Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa
Coherus shares surge on $558M Udenyca divestiture deal - Investing.com
Unusually active option classes on open December 3rd - TipRanks
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - The Malaysian Reserve
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Inkl
Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M - TipRanks
Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta - XM
Coherus Biosciences Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):